← Back to Search

Other

CST-2032 and CST-107 for Dementia

Phase 2
Recruiting
Research Sponsored by CuraSen Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline after 14 days of treatment

Summary

This trial is testing two drugs, CST-2032 and CST-107, to see if they can help people with early memory and thinking problems. The drugs aim to improve brain cell function or protect them, potentially improving memory and thinking skills.

Eligible Conditions
  • Mild Cognitive Impairment
  • Dementia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline after 14 days of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline after 14 days of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Electrocardiograms (ECGs)
Treatment-emergent adverse events
Vital Signs
Secondary study objectives
Change from Baseline in CANTAB Adaptive Tracking Task
Change from Baseline in CANTAB Paired Associates Learning Test
Change from Baseline in CANTAB Rapid Visual Information Processing
+4 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Placebo to CST-2032 (6mg)/CST-107 (3mg)Experimental Treatment1 Intervention
Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days.
Group II: Placebo to CST-2032 (3mg)/CST-107 (3mg)Experimental Treatment1 Intervention
Subjects will receive matching placebo for CST-2032 and matching placebo for CST-107 for 14 days followed by a washout period of no drug for 7 days, followed by daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days.
Group III: CST-2032 (6mg)/CST-107 (3mg) to PlaceboExperimental Treatment1 Intervention
Subjects will receive daily doses of CST-2032 (6mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.
Group IV: CST-2032 (3mg)/CST-107 (3mg) to PlaceboExperimental Treatment1 Intervention
Subjects will receive daily doses of CST-2032 (3mg) co-administered with CST-107 (3mg) for 14 days, followed by a washout period of no drug for 7 days, followed by matching placebo for CST-2032 and matching placebo for CST-107 for 14 days.

Find a Location

Who is running the clinical trial?

CuraSen Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
41 Total Patients Enrolled
Chief Medical OfficerStudy DirectorCuraSen Therapeutics, Inc.
126 Previous Clinical Trials
21,931 Total Patients Enrolled

Media Library

CST-107 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05104463 — Phase 2
Mild Cognitive Impairment Research Study Groups: CST-2032 (6mg)/CST-107 (3mg) to Placebo, CST-2032 (3mg)/CST-107 (3mg) to Placebo, Placebo to CST-2032 (3mg)/CST-107 (3mg), Placebo to CST-2032 (6mg)/CST-107 (3mg)
Mild Cognitive Impairment Clinical Trial 2023: CST-107 Highlights & Side Effects. Trial Name: NCT05104463 — Phase 2
CST-107 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05104463 — Phase 2
Mild Cognitive Impairment Patient Testimony for trial: Trial Name: NCT05104463 — Phase 2
~17 spots leftby Nov 2025